These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7726501)

  • 1. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.
    Bechtold CM; Patick AK; Alam M; Greytok J; Tino JA; Chen P; Gordon E; Ahmad S; Barrish JC; Zahler R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):374-9. PubMed ID: 7726501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
    Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
    Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.
    Patick AK; Mo H; Markowitz M; Appelt K; Wu B; Musick L; Kalish V; Kaldor S; Reich S; Ho D; Webber S
    Antimicrob Agents Chemother; 1996 Feb; 40(2):292-7. PubMed ID: 8834868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
    McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
    Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
    Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An HIV-1 protease screening assay using a non-infectious proviral clone.
    Heldsinger AA; Antonucci T
    J Virol Methods; 1994 Oct; 49(3):247-55. PubMed ID: 7868643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
    Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
    Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
    Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
    Lamarre D; Croteau G; Wardrop E; Bourgon L; Thibeault D; Clouette C; Vaillancourt M; Cohen E; Pargellis C; Yoakim C; Anderson PC
    Antimicrob Agents Chemother; 1997 May; 41(5):965-71. PubMed ID: 9145853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of protease inhibitors on HIV-1 maturation and infectivity.
    Jardine DK; Tyssen DP; Birch CJ
    Antiviral Res; 2000 Jan; 45(1):59-68. PubMed ID: 10774590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.
    Rayner MM; Cordova BC; Meade RP; Aldrich PE; Jadhav PK; Ru Y; Lam PY
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1635-40. PubMed ID: 7979297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.
    Schätzl H; Gelderblom HR; Nitschko H; von der Helm K
    Arch Virol; 1991; 120(1-2):71-81. PubMed ID: 1929879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.